Effects of soy milk consumption on gut microbiota, inflammatory markers, and disease severity in patients with ulcerative colitis: a study protocol for a randomized clinical trial

(2020) Effects of soy milk consumption on gut microbiota, inflammatory markers, and disease severity in patients with ulcerative colitis: a study protocol for a randomized clinical trial. Trials.

[img]
Preview
Text
13549.pdf

Download (1MB) | Preview

Abstract

BackgroundSeveral strategies are recommended to alleviate clinical symptoms of ulcerative colitis (UC). Soy milk may affect UC through its anti-inflammatory properties. However, no study has examined the effects of soy milk consumption on gut microbiota and inflammatory biomarkers in patients with UC. The current study will be done to examine the effects of soy milk consumption on UC symptoms, inflammation, and gut microbiota in patients with UC.MethodsThis study is a randomized clinical trial, in which thirty patients with mild to moderate severity of UC will be randomly allocated to receive either 250mL/day soy milk plus routine treatments (n=15) or only routine treatments (n=15) for 4weeks. Assessment of anthropometric measures and biochemical indicators including serum concentrations of high-sensitivity C-reactive protein (hs-CRP), tumor necrosis factor-alpha (TNF-alpha), interleukin-1 beta (IL-1 beta), and interferon gamma (IFN-gamma) will be done at the study baseline and end of trial. In addition, the quantity of butyrate-producing bacteria including Clostridium cluster IV, Faecalibacterium prausnitzii, and Roseburia spp.; prebiotic bacteria including Lactobacillus spp. and Bifidobacteria spp.; and mucus-degrading bacteria including Akkermansia muciniphila, Bacteroides fragilis, and Ruminococcus spp., as well as calprotectin and lactoferrin levels, will be explored in fecal samples. Also, the Firmicutes to Bacteroidetes ratio which is of significant relevance in human gut microbiota composition will be assessed.DiscussionAltered gut microbiota has been reported as an important contributing factor to inflammation in patients with inflammatory bowel disease (IBD). Soy milk contains several components such as phytoestrogens with potential anti-inflammatory properties. This product might affect gut microbiota through its protein and fiber content. Therefore, soy milk might beneficially affect systemic inflammation, gut microbiota, and then clinical symptoms in patients with UC.Trial registrationIranian Registry of Clinical Trials (www.irct.ir) IRCT20181205041859N1. Registered on 27 January 2019.

Item Type: Article
Keywords: Soy milk Inflammation Microbiota RCT Ulcerative colitis BOWEL-DISEASE FECAL MICROBIOTA BARRIER FUNCTION SERUM-LEVELS PROTEIN DIET DISABILITY BURDEN BIFIDOBACTERIUM DISORDERS
Subjects: QU Biochemistry. Cell Biology and Genetics > QU 145-220 Nutrition. Vitamins
WI Digestive System
Divisions: Food Security Research Center
Gastroenterology and Liver Research Center
School of Nutrition and Food Sciences > Department of Community Nutrition
Journal or Publication Title: Trials
Journal Index: ISI
Volume: 21
Number: 1
Identification Number: https://doi.org/10.1186/s13063-020-04523-8
Depositing User: Zahra Otroj
URI: http://eprints.mui.ac.ir/id/eprint/13549

Actions (login required)

View Item View Item